The acquisition of zentalist pharmaceuticals company Zentalis by pharmaceuticals group Sandoz Pharmas, is expected to result in significant benefits to Indian pharmaceutical industry.
The acquisition will create an opportunity to accelerate the growth of India’s pharmaceutical sector and provide significant benefit to Indian stakeholders.
According to a company spokesperson, Sandoz, the combined entity will have a combined portfolio of over 4,000 pharmaceutical products and services that span an array of therapeutic products, from vaccines and medicines to diagnostics and medicines.
The company has more than 60 employees and approximately 10 million clients in over 130 countries worldwide.
The new entity will also create opportunities to expand our portfolio to include vaccines and medical devices, according to the company.
Sandoz is an emerging leader in biopharmaceuticals, including vaccines and pharmaceuticals.
Sandoz currently operates two drug discovery and development programs.
The pharmaceuticals are currently focused on developing and manufacturing new vaccines, as well as developing and developing new medicines.
This is the first acquisition by Sandaz pharmaceuticals for the healthcare sector in India, the company said.
Sandaz is focused on pharmaceutical development, and Sandoz has a long track record of success with its pharma business.
Currently, Sandaz has a portfolio of medicines in the following areas: Neuro-Oncology: Neuro Oncology is an important area for the Company in terms of research and development and a strong business opportunity for us.
We are very excited about the opportunities to advance the Company’s clinical development program.
Patent and Patent Applications: Sandaz has extensive patents and patent applications across its product portfolio.
Sandoz is committed to supporting the development of its patents through its patent portfolio.
Finance and Accounting: The Company has been in financial position for more than 40 years.
In 2018, we made a strong profit for the first time ever and also raised a $3.9 billion Series B financing round led by Chinese Investment Capital.
The financing round also resulted in Sandoz obtaining over $1.4 billion in debt financing.
As of September 2020, the Company had net cash position of $7.9 million.
Our strategy is to grow our product portfolio to support our customers’ needs and achieve our vision of developing new products, which is why we have made the acquisition of Zentalís pharmaceuticals business.
Sandos goal is to provide a strong and reliable product offering, and we are confident that we can provide the same quality of product that our customers expect.
About Sandoz pharmaceutical products, company spokesperson said, The acquisition of Sandoz and Zentalists pharmaceuticals is expected, which will result in synergies in the supply chain and the pharmaceutical products’ market penetration, the spokesperson said.
As the company expands into healthcare, we will enhance the strength of our pharma portfolio to meet the needs of our customers.
Sandaz is a diversified company with a strong focus on providing innovative medicines to healthcare customers in India.
Sando has over 70 years of experience in the pharmaceutical industry and has developed over 500 products in the healthcare space.
Zentalis, a subsidiary of Sandaz, has been operating in the biopharma space since 2003.
The Company has over 2,200 employees across 70 offices and a market capitalization of $2.2 billion.